AMLX Stock — Amylyx Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$32.41

Market cap

$4,066.1M

Cash

$722.5M

Enterprise value

$3,343.6M

Balance sheet

Cash	$722.5M
Debt	$0.0M
Net cash	$722.5M
Enterprise value	$3,343.6M
Basic shares	111.4M shares
Fully diluted shares	133.8M shares
Fully diluted market cap	$4,336.6M
Cash per share	$6.49

Cash figures as of 2026-08-21. Database snapshot: 2026-09-21.

Price history

Loading AMLX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 15 - Apr 26	AMX0114	Phase 1	ALS	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

avexitide

Phase 3 · Active Modality: GLP-1 receptor antagonist

Target GLP-1 receptor

Indications

Post-bariatric hypoglycemia (PBH) (Phase 3)
Congenital hyperinsulinism (congenital HI) (Stage not disclosed)

Status note Lead investigational asset; first-in-class GLP-1 receptor antagonist. LUCIDITY (NCT06747468): 78-participant Phase 3 in PBH post-RYGB at 21 U.S. sites. Expanded Access Program initiated May 2026 for U.S. adults with PBH post-RYGB.

AMX0035

Phase 2 · Active Modality: oral fixed-dose combination of sodium phenylbutyrate and taurursodiol

Target ER stress and mitochondrial dysfunction

Indications

Wolfram syndrome (Phase 2)
Progressive supranuclear palsy (PSP) (Phase 2)

Status note HELIOS open-label Phase 2 in Wolfram syndrome ongoing; company working with FDA on a Phase 3. Phase 2b/3 in PSP discontinued and winding down.

AMX0114

Phase 1 · Active Modality: antisense oligonucleotide (ASO)

Target CAPN2 (calpain-2)

Indications

Amyotrophic lateral sclerosis (ALS) (Phase 1)

Status note LUMINA (NCT06665165): multinational multiple-ascending-dose Phase 1 in ALS; Cohort 1 biomarker data presented Jun 2026. FDA Fast Track Designation.

AMX0318

Preclinical · Active Modality: GLP-1 receptor antagonist (long-acting)

Target GLP-1 receptor

Partnerships Gubra A/S: collaboration and license agreement (Dec 2024) for long-acting GLP-1 receptor antagonist R&D; second research collaboration Jul 2026 for a rare endocrine disease

Indications

PBH and other rare diseases (Preclinical)

Status note Selected as development candidate Jan 2026 after preclinical evaluation; IND-enabling studies planned/ongoing.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Avexitide
Lead indication	Post Bariatric Hypoglycemia
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06747468	Phase 3	Active, not recruiting	Sponsor	AMLX	—	Post Bariatric Hypoglycemia	—
NCT05676034	Phase 2	Active, not recruiting	Sponsor	AMLX	—	Wolfram Syndrome	—
NCT06665165	Phase 1	Recruiting	Sponsor	AMLX	—	ALS	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Amylyx Pharmaceuticals Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	494,378	-506,226	0.42%	2026-08-14
Logos Global Management	350,000	-350,000	0.27%	2026-08-14
OrbiMed Advisors	183,400	+183,400	0.06%	2026-08-14
Ikarian Capital	117,500	+117,500	0.35%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

AMLX — Amylyx Pharmaceuticals Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders